Cadila Healthcare is currently trading at Rs. 339.25, up by 6.55 points or 1.97% from its previous closing of Rs. 332.70 on the BSE.
The scrip opened at Rs. 332.60 and has touched a high and low of Rs. 342.95 and Rs. 332.60 respectively. So far 96520 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 432.40 on 10-Sep-2018 and a 52 week low of Rs. 306.35 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 342.95 and Rs. 321.05 respectively. The current market cap of the company is Rs. 34761.18 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.33% and 7.88% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Atenolol and Chlorthalidone Tablets USP (US RLD-Tenoretic), 50 mg/25 mg and 100 mg/25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. Atenolol belongs to a class of drugs known as beta blockers. Chlorthalidone is a ‘water pill’ (diuretic) and causes the body to get rid of extra salt and water. It also helps to relax the blood vessels so that blood can flow easily.
The group now has 253 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: